Skip to main content
TipRanks
Go Ultimate75% OFF

Bright Minds Biosciences (DRUG) AI Stock Analysis

77 Followers
TSE:DRUG

Bright Minds Biosciences

(CNQX:DRUG)

Select Model
Rating:47Neutral
Price Target:CAD 84.00â–²(190.46% Upside)
Action:reiterated
Date:05/21/26

Overall score is held back primarily by pre-revenue operations, widening losses, and elevated cash burn despite a strong, low-debt balance sheet. Technical indicators are broadly neutral-to-weak, and valuation is constrained by negative earnings and no dividend yield data.

Positive Factors
Low leverage and capital baseExtremely low debt reduces refinancing pressure and preserves financial flexibility while the company advances its pipeline. The substantially larger equity base also indicates capital has been raised to support development, providing a stronger funding foundation than a highly leveraged balance sheet.
Negative Factors
No operating revenueWithout marketed products or recurring operating revenue, Bright Minds cannot currently fund development from its business operations. Its financial outlook therefore remains tied to future clinical and commercial success, while ongoing research spending must be supported by existing capital or additional financing.

Bright Minds Biosciences (DRUG) vs. iShares MSCI Canada ETF (EWC)

-75%-50%-25%0%25%50%75%TSE:DRUG-64.92%EWC+16.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 285.27M
Dividend Yield
―
Average Volume (3M)
1,159
Price to Earnings (P/E)
-10.0
Beta (1Y)
1.72
Revenue Growth
―
EPS Growth
-117.77%
Country
Canada
Employees
26
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Bright Minds Biosciences Business Overview & Revenue Model

Company Description

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...

How the Company Makes Money

Bright Minds Biosciences does not appear to have a mature, recurring commercial product revenue base because it is a clinical-stage drug developer. As a result, its ability to generate revenue and fund operations is typically driven by (a) capital ra...

Bright Minds Biosciences Financial Statement Overview

Summary

Balance sheet is strong with minimal debt and substantial equity, but overall financial performance is pressured by pre-revenue operations, widening net losses (TTM about -$27.5M), and increased cash burn (TTM free cash flow about -$20.1M), which elevates funding/dilution risk.

Income Statement

12Very Negative

Balance Sheet

64Positive

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMSep 2025Dec 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue000000
Gross Profit-40.10K00000
EBITDA-33.94M-12.15M-2.73M-7.30M-14.96M-27.64K
Net Income-24.75M-12.23M-2.80M-7.37M-14.96M-8.65M
Balance Sheet
Total Assets310.84M84.42M6.10M6.88M12.09M20.04M
Cash, Cash Equivalents and Short-Term Investments308.33M82.91M5.72M6.75M11.63M19.76M
Total Debt65.70K125.78K118.96K73.55K139.91K0
Total Liabilities2.55M2.38M568.26K280.86K1.54M638.57K
Stockholders Equity308.30M82.04M5.54M6.60M10.54M19.40M
Cash Flow
Free Cash Flow-25.00M-8.69M-1.85M-7.02M-13.59M-7.32M
Operating Cash Flow-25.00M-8.69M-1.85M-7.02M-13.59M-7.32M
Investing Cash Flow000000
Financing Cash Flow277.00M85.57M810.57K2.19M5.20M26.06M

Bright Minds Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price28.92

Price Trends

50DMA66.88Negative
100DMA85.25Negative
200DMA96.84Negative

Market Momentum

MACD-12.44Positive
RSI25.25Positive
STOCH58.37Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DRUG, the sentiment is Negative. The current price of 28.92 is below the 20-day moving average (MA) of 48.82, below the 50-day MA of 66.88, and below the 200-day MA of 96.84, indicating a bearish trend. The MACD of -12.44 indicates Positive momentum. The RSI at 25.25 is Positive, neither overbought nor oversold. The STOCH value of 58.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DRUG.

Bright Minds Biosciences Risk Analysis

Bright Minds Biosciences disclosed 26 risk factors in its most recent earnings report. Bright Minds Biosciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Bright Minds Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:DRUG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:DRUGTSE:DRUG47NeutralCAD 293.58M-9.97-12.56%――-117.77%

* Healthcare Sector Average

Performance Comparison

0%100%200%TSE:DRUGTSE:MYNDTSE:IBOTSE:MBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:DRUG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:DRUGBright Minds Biosciences Inc.28.92-51.75-64.15%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:IBOUniversal Ibogaine Inc0.010.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.07-0.81-92.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: May 21, 2026